Skip to main content

Table 3 Primary and secondary outcomes in T2DM with ACS at the end of follow-up

From: Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

Outcome

Number of event (%)

Linagliptin vs. control

Linagliptin (n = 154)

Control

(n = 308)

HR (95% CI)

P

Primary outcomes

 6 month follow-up

  Cardiovascular death

5 (3.2)

11 (3.6)

.83 (.29, 2.40)

.735

  Non-fatal myocardial infarction

6 (3.9)

8 (2.6)

1.38 (.48, 3.99)

.547

  Non-fatal ischemic stroke

1 (.6)

3 (1.0)

.62 (.06, 5.95)

.678

  Primary composite outcomea

10 (6.5)

22 (7.1)

.84 (.40, 1.78)

.648

 At the end of follow-up

  Cardiovascular death

8 (5.2)

13 (4.2)

1.13 (.47, 2.73)

.781

  Non-fatal myocardial infarction

7 (4.5)

10 (3.2)

1.29 (.49, 3.38)

.610

  Non-fatal ischemic stroke

3 (1.9)

3 (1.0)

1.89 (.38, 9.34)

.438

  Primary composite outcomea

15 (9.7)

26 (8.4)

1.08 (.57, 2.03)

.821

Secondary outcomes

 All-cause mortality

13 (8.4)

23 (7.5)

1.07 (.54, 2.12)

.840

 Other cardiovascular outcomes

  Hospitalization for heart failure

16 (10.4)

22 (7.1)

1.41 (.74, 2.69)

.292

  Percutaneous coronary intervention

23 (14.9)

30 (9.7)

1.48 (.86, 2.54)

.160

  Coronary artery bypass grafting

4 (2.6)

6 (1.9)

1.25 (.35, 4.44)

.727

 Safety outcomes

  Hypoglycemia

6 (3.9)

8 (2.6)

1.43 (.50, 4.12)

.509

  DKA or HHS

1 (.6)

2 (.6)

.96 (.09, 10.54)

.970

  Acute pancreatitis

0 (.0)

0 (.0)

NA

NA

  De novo dialysis

10 (6.5)

16 (5.2)

1.31 (.59, 2.89)

.512

  Acute hepatitis

2 (1.3)

0 (.0)

NA

NA

  Newly diagnosed malignancy

1 (.6)

5 (1.6)

.38 (.04, 3.25)

.377

  1. ACS acute coronary syndrome, CI confidence interval, CV cardiovascular, DKA diabetic ketoacidosis, HHS hyperosmolar hyperglycemic state, HR hazard ratio, NA not applicable, T2DM type 2 diabetes mellitus
  2. aAnyone of cardiovascular death, non-fatal myocardial infarctionand non-fatal ischemic stroke